Browse All

Current Filters

CLEAR FILTER x

TITLE

Long-term Safety and Efficacy of IPX203 in Parkinson’s Disease Patients with Motor Fluctuations: A 9-Month Open-label Extension Trial

Author:Espay, Alberto   Hauser, Robert   Dhall, Rohit   Thakkar, Sandeep   Cloud, Leslie   Banisadr, Ghazal   Fisher, Stanley   Visser, Hester   

Session Name:S32: Movement Disorders: Trials  

Topic:Movement Disorders  

Program Number:S32.006  

Author Institution:University of Cincinnati, Cincinnati, OH  Movement Disorders Center, Tampa, FL  University of Arkansas for Medical Sciences, Little Rock, AR  Hoag, Newport Beach, CA  VCU, Richmond, VA  Amneal Pharmaceuticals, Chicago, IL  Amneal Pharmaceuticals, Bridgewater, NJ  Amneal Pharmaceuticals, Piscataway, NJ  

Integrated safety summary from Phase 3 clinical trials of IPX203, an extended-release carbidopa-levodopa formulation, in Parkinson disease

Author:Fernandez, Hubert   Hauser, Robert   Hinson, Vanessa   Pavasia, Nirav   Molho, Eric   Zeitlin, Leonid   Visser, Hester   D'Souza, Richard   

Session Name:P1: Movement Disorders: Clinical Trials in Parkinson's Disease 1  

Topic:Movement Disorders  

Program Number:P1.006  

Author Institution:Center for Neurological Restoration, Cleveland Clinic, Cleveland, OH  Movement Disorders Center, Tampa, FL  MUSC, Charleston, SC  Neurology Consultants of Dallas, Dallas, TX  Parkinson's Disease & Movement Dis Ctr, Albany, NY  Quartesian LLC, Princeton, NJ  Amneal Pharmaceuticals, Piscataway, NJ  Amneal Pharmaceuticals, Bridgewater, NJ